Interviews on Fox Business and other programs discussed issues surrounding the novel strain of the coronavirus and the Company’s plan to provide a diagnostic solution
Salt Lake City, Utah – January 30, 2020 – The CEO of Co-Diagnostics, Inc. (Nasdaq:CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, has recently participated in interviews with hosts of programs on Fox Business and Yahoo! Finance to discuss the current outbreak of the novel coronavirus that originated in China and continues to raise concerns worldwide.
Currently, the number of confirmed infections in China have surpassed 7,700, quadrupling since the weekend, and caused 170 deaths. According to the Centers for Disease Control and Prevention, cases of the new coronavirus, “2019-nCoV,” have been confirmed in 19 countries since the virus was first identified in China on January 7, 2020, including 5 positive infections in the US and suspected cases in 36 states.
Topics in the interviews on Fox Business and Yahoo! Finance ranged from issues related to detecting the virus, the importance of a quality diagnostic, and Company competitive advantages and infrastructure that the Company will leverage to bring the product to market.
Regarding the interviews, Co-Diagnostics CEO Dwight Egan commented “We believe that the competitive advantages of our CoPrimer™ technology platform and rapid development process have positioned the Company to provide a high–quality, economic solution to this ongoing health crisis.”
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a new, state-of-the-art diagnostics technology. The Company’s technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.
This press release contains forward-looking statements. Forward-looking statements can be identified by words such as “believes,” “expects,” “estimates,” “intends,” “may,” “plans,” “will” and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Forward-looking statements in this release may include statements regarding the (i) use of funding proceeds, (ii) expansion of product distribution, (iii) acceleration of initiatives in certain verticals or markets, (iv) capital resources and runway needed to advance the Company’s products and markets, (v) increased sales in the near-term, (vi) flexibility in managing the Company’s balance sheet, (vii) anticipation of business expansion, and (viii) benefits in research and worldwide accessibility of the CoPrimer technology and its cost-saving and scientific advantages. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances. Actual results may differ materially from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
Co-Diagnostics Investor Relations
Coltrin & Associates, Inc